EGFR and non-small cell lung carcinoma: Therefore, EGFR mutation type can not be considered as a predictive biomarker for the effect of LRT in the specific OMD setting as an EGFR exon 19 mutation is also associated with better survival in patients treated with TKI in advanced EGFR-mutated NSCLC.25